Novartis antimalarial medicine Coartem® 80/480mg received World Health Organization (WHO) prequalification, making it the first and only high strength (80/480mg) Artemisinin-based Combination Therapy (ACT) antimalarial treatment available for public sector procurement. This new dosage strength*, has the potential to improve malaria management. WHO prequalification of Coartem® 80/480mg now allows for broad-scale public sector procurement, possibly providing access to the treatment to as many as 25 million malaria sufferers across Africa.
Although preventable and treatable, malaria was responsible for approximately 584,000 deaths in 2013.One Coartem® 80/480mg tablet is bioequivalent to four tablets of Coartem® 20/120mg resulting in a lower pill burden for patients - six tablets for completion of the course of treatment, compared to the previous 24. Studies have shown that patient adherence to ACTs varies considerably, from 39% to 100%. Failure to complete the full treatment course may reduce treatment efficacy and allow malaria parasites to develop resistance to the drug. The reduction in the number of tablets associated with Coartem® 80/480mg could increase convenience and overcome the challenges associated with therapies that require taking a large number of pills, therefore improving adherence to treatment and clinical effectiveness.
Coartem® 80/480mg, which received Swissmedic approval in November 2013, was launched in the private sector in Nigeria in late 2013 and has since been launched in more than ten African countries. This latest formulation highlights the efforts of Novartis to expand access to essential malaria treatments for all ages: in 2004 Coartem® 20/120mg was the first fixed-dose ACT prequalified by the WHO and in 2009, Coartem®Dispersible was launched as the first dispersible ACT designed specifically for infants and children. Today, more than 700 million treatments, including 250 million Coartem®Dispersible antimalarials, have been delivered without profit to malaria-endemic countries.
